U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07032532) titled 'Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)' on May 19.
Brief Summary: This study will treat patients with newly diagnosed PTCL, who have no prior systemic treatment for T-cell lymphoma. This study will assess the anti-tumor efficacy of golidocitinib using 2-year Progression-Free Survival rate as primary endpoint. In addition, it will help to understand what type of side effects may occur with the drug treatment.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Peripheral T Cell Lymphoma
Intervention:
DRUG: Golidocitinib
Golidoc...